Castle Hook Partners’s Adverum Biotechnologies ADVM Stock Holding History

Castle Hook Partners’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-108,255	Closed	-$6.55M	–	40
2018 Q3	$6.55M	Buy	108,255 +26,087	+32%	+$1.47M	0.19%	41
2018 Q2	$4.36M	Buy	82,168 +24,390	+42%	+$1.47M	0.15%	41
2018 Q1	$3.35M	Buy	+57,778	New	+$3.6M	0.24%	44

Other funds holding ADVM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Castle Hook Partners's ADVM Position: Q4 2018 in Review

Castle Hook Partners sold out of Adverum Biotechnologies (ADVM) in Q4 2018, closing a stake of 108,255 shares — an estimated $6.55M sold.

Castle Hook Partners first reported a position in ADVM in Q1 2018 and held it in 3 quarters. The position peaked at $6.55M in Q3 2018. 86 funds tracked by Wall St. Rank hold ADVM as of Q4 2018.

Castle Hook Partners reported no remaining Adverum Biotechnologies position as of Q4 2018 after selling out during the quarter.
Castle Hook Partners sold 108,255 Adverum Biotechnologies shares in Q4 2018, an estimated $6.55M.
Castle Hook Partners first reported a position in Adverum Biotechnologies in Q1 2018 and held it in 3 quarters.
Castle Hook Partners's Adverum Biotechnologies position peaked at $6.55M in Q3 2018.
86 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2018.

Based on Castle Hook Partners's 13F filing for Q4 2018, filed 14 Feb 2019.